2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06D.03 Concurrent Liquid and Tissue Biopsy from Same Laboratory Increases On-Label Alteration Detection with Faster Turnaround Time

EP.06D.03 Concurrent Liquid and Tissue Biopsy from Same Laboratory Increases On-Label Alteration Detection with Faster Turnaround Time

Back to course

Pdf Summary

This study, conducted by a team at Guardant Health and Memorial Cancer Institute, explores the effectiveness of using both liquid biopsy (LB) and tissue biopsy (TB) concurrently for detecting actionable alterations (AA) in patients with advanced non-small cell lung cancer (NSCLC). Recent guidelines from the National Comprehensive Cancer Network (NCCN) have endorsed using both methods either together or as reflex tests. <br /><br />The research analyzed data from 4/2022 to 11/2023, examining two cohorts: one where both LB and TB were reported within six months (1,200 patients), and another where only LB was reported due to the non-completion of TB (2,389 patients). The findings revealed that using both LB and TB identified on-label alterations in 34% of patients, with 66% of actionable alterations found in both types of biopsies. Notably, LB provided a faster turnaround time, with a median difference of eight days compared to TB.<br /><br />Furthermore, liquid biopsies detected on-label alterations even when TBs weren’t completed, though such alterations had a median max variant allele frequency (maxVAF) of 1%. In cases where TB was not completed, LBs still detected alterations in 26% of the patients. Reasons for non-completion of TB included missing information, samples not sent, patient death, or test cancellation.<br /><br />The study underscores the utility of a combined LB and TB strategy, especially considering the faster results and potential limitations of tissue biopsies. This concurrent testing approach captures a higher number of on-label alterations and highlights the potential for liquid biopsy to serve more effectively in delivering genomic test results, especially in scenarios where tissue biopsies are impractical. The research supports the increasing adoption of LB and TB testing to optimize precision treatment in NSCLC.

Asset Subtitle

Sean Gordon

Meta Tag

Speaker Sean Gordon

Topic Pathology and Biomarkers

Keywords

liquid biopsy

tissue biopsy

non-small cell lung cancer

actionable alterations

Guardant Health

Memorial Cancer Institute

National Comprehensive Cancer Network

precision treatment

genomic test results

concurrent testing